Leap Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Leap Therapeutics şirketinin toplam hissedar öz sermayesi $49.0M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $65.0M ve $16.1M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$62.82m
Eşitlik	US$48.95m
Toplam yükümlülükler	US$16.09m
Toplam varlıklar	US$65.05m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 5MC 'nin kısa vadeli varlıkları ( $63.8M ) kısa vadeli yükümlülüklerini ( $16.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: 5MC un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 5MC borçsuzdur.

Borcun Azaltılması: 5MC un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 5MC şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: 5MC serbest nakit akışı her yıl % 14.4 1.1 yıl yetecek nakit akışına sahip olacaktır.

Leap Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Leap Therapeutics Announces Reverse Stock Split to Meet the Minimum Nasdaq Listing Price Per Share Requirements

Recent updates

Leap Therapeutics, Inc. Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics, Inc., Annual General Meeting, Jul 02, 2024

Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP

Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium

Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Leap Therapeutics, Inc. Announces Initiation of Randomized Controlled Part B of the Defiance Study of DKN-01 in Colorectal Cancer Patients

Leap Therapeutics Announces Reverse Stock Split to Meet the Minimum Nasdaq Listing Price Per Share Requirements

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

Leap Therapeutics, Inc. (NasdaqGM:LPTX) acquired Flame Biosciences, Inc from Acuta Capital Partners LLC, Adage Capital Management, L.P., Cormorant Asset Management, LP, Cormorant Asset Management, LP, Terra Magnum Capital Partners and others.

Leap Therapeutics, Inc. Appoints Atricia Martin and Christian Richard to Board of Directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.14 loss in 3Q 2021)

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Leap Therapeutics, Inc. Announces First Patient Enrolled in Defiance Study of Dkn-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 Distinguish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Leap Therapeutics, Inc. Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq at the ESMO Congress

First half 2022 earnings released

Leap Therapeutics, Inc. Resigns Dr. Monica Bertagnolli, as Director

Leap Therapeutics and BeiGene, Ltd. Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer

Leap Therapeutics, Inc. to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting

First quarter 2022 earnings released: US$0.092 loss per share (vs US$0.12 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Leap Therapeutics to Present Positive New Data from the Distinguish Study of DKN-01 Plus Tislelizumab at the Asco GI Cancers Symposium

Insufficient new directors

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.092 loss in 3Q 2020)

Leap Therapeutics to Present New Data from the Distinguish Study of Dkn-01 Plus Tislelizumab At the Esmo 2021 Congress

First half 2021 earnings released: US$0.24 loss per share (vs US$0.57 loss in 1H 2020)

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.55 loss in 1Q 2020)

Leap Therapeutics, Inc. Provides DKN-01 Development Update

Revenue misses expectations

New 90-day high: €2.18

New 90-day high: €2.00

New 90-day low: €1.27

Leap Therapeutics, Inc. Announces the Presentation of Clinical Data from Its Phase 1b/2a Clinical Trial of DKN-01 in Patients with Advanced Esophagogastric Cancer

New 90-day high: €1.84

Leap Therapeutics, Inc. announced that it has received $26.985796 million in funding from Perceptive Advisors LLC, BeiGene, Ltd., Baker Bros. Advisors LP

Leap Therapeutics, Inc. Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer

Leap Therapeutics and Beigene Announces First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer

New 90-day low - €1.50

New 90-day low - €1.52

Leap Therapeutics, Inc.(NasdaqGM:LPTX) dropped from Russell Microcap Value Index

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin